Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00288
|
|||||
| Drug Name |
Bosentan
|
|||||
| Synonyms |
4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulfornamide; 4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl)benzenesulfornamide; 4-t-butyl-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide; 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl]benzenesulfonamide; 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamide; Actelion; Bosentan (INN); Bosentan [USAN:INN:BAN]; Bosentanum; KS-5062; P-tert-Butyl-N-(6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamide; P-tert-Butyl-N-[6-(2-hydroxyethoxy); Ro 47-0203; Ro 47-0203/039; Ro-47-0203; Ro-47-0203/029; Ro-47-0203/039; Tracleer; Tracleer (TN)
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Pulmonary arterial hypertension [ICD11: BB01.0] | Approved | [1] | |||
| Therapeutic Class |
Antihypertensive Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C27H29N5O6S
|
|||||
| Canonical SMILES |
CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC
|
|||||
| InChI |
InChI=1S/C27H29N5O6S/c1-27(2,3)18-10-12-19(13-11-18)39(34,35)32-23-22(38-21-9-6-5-8-20(21)36-4)26(37-17-16-33)31-25(30-23)24-28-14-7-15-29-24/h5-15,33H,16-17H2,1-4H3,(H,30,31,32)
|
|||||
| InChIKey |
GJPICJJJRGTNOD-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 147536-97-8
|
|||||
| Pharmaceutical Properties | Molecular Weight | 551.6 | Topological Polar Surface Area | 154 | ||
| Heavy Atom Count | 39 | Rotatable Bond Count | 11 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 11 | |||
| XLogP |
3.8
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10233650
, 103250068
, 103956688
, 104179184
, 104373115
, 118855338
, 12014838
, 125341362
, 126592988
, 126624339
, 126655593
, 126671144
, 127344134
, 127344135
, 127344136
, 127963291
, 131299472
, 134337358
, 134339787
, 135143300
, 135723687
, 137003210
, 142094009
, 143493318
, 144115748
, 144205997
, 14763764
, 151991482
, 152237729
, 152258948
, 160647793
, 160963904
, 44434454
, 46507154
, 47285934
, 48179783
, 49831038
, 49881484
, 50112694
, 50840650
, 51091861
, 53787963
, 56464382
, 57337889
, 7978805
, 85209778
, 92309270
, 92714194
, 93581179
, 93619683
|
|||||
| ChEBI ID |
ChEBI:51450
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | OATP1B1 | Transporter Info | Organic anion transporting polypeptide 1B1 | Substrate | [2] | |
| OATP1B3 | Transporter Info | Organic anion transporting polypeptide 1B3 | Substrate | [2] | ||
| OATP2B1 | Transporter Info | Organic anion transporting polypeptide 2B1 | Substrate | [2] | ||
| Drug-Transporter Activity Data | ||||||
| Drug-Transporter Activity Data | OATP1B1 | Transporter Info | Km = 44 microM | Chinese hamster ovary (CHO) cells-OATP1B1 | [2] | |
| OATP1B3 | Transporter Info | Km = 141 microM | Chinese hamster ovary (CHO) cells-OATP1B3 | [2] | ||
| OATP2B1 | Transporter Info | Km = 202 microM | Chinese hamster ovary (CHO) cells-OATP2B1 | [2] | ||
| References | ||||||
| 1 | Bosentan was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007 Aug;35(8):1400-7. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.